Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab for Severe VWD and VWD/Hemophilia A
NCT05500807Phase 1Recruiting
- Sponsor
- Bleeding and Clotting Disorders Institute
- Start
- Nov 2022
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emicizumab in von Willebrand disease (VWD) and hemophilia A, sponsored by Bleeding and Clotting Disorders Institute. Primary endpoints: Efficacy for prophylaxis at 18 months and Safety for prophylaxis at 18 months. Started Nov 2022; status: recruiting.
02
Drugs
emicizumab
03
Conditions
von Willebrand disease (VWD)hemophilia A
Beyond the preview
Go deeper on NCT05500807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05500807.